A workshop on measuring the progression of atrophy secondary to stargardt disease in the progstar studies: Findings and lessons learned

ProgStar Study Group

Research output: Contribution to journalArticle

Abstract

The Progression of Atrophy Secondary to Stargardt Disease (ProgStar) studies were designed to measure the progression of Stargardt disease through the use of fundus autofluorescence imaging, optical coherence tomography, and microperimetry. The overarching objectives of the studies were to document the natural course of Stargardt disease and identify the most appropriate clinical outcome measures for clinical trials assessing the efficacy and safety of upcoming treatments for Stargardt disease. A workshop organized by the Foundation Fighting Blindness Clinical Research Institute was held on June 11, 2018, in Baltimore, MD, USA. Invited speakers discussed spectral-domain optical coherence tomography, fundus autofluorescence, and microperimetry methods and findings in the ProgStar prospective study. The workshop concluded with a panel discussion of optimal endpoints for measuring treatment efficacy in Stargardt disease. We summarize the workshop presentations in light of the most current literature on Stargardt disease and discuss potential clinical outcome measures and endpoints for future treatment trials.

Original languageEnglish (US)
Article number16
JournalTranslational Vision Science and Technology
Volume8
Issue number2
DOIs
StatePublished - Mar 1 2019

Fingerprint

Atrophy
Education
Optical tomography
Optical Coherence Tomography
Outcome Assessment (Health Care)
Baltimore
Optical Imaging
Blindness
Stargardt disease 1
Clinical Trials
Prospective Studies
Safety
Imaging techniques

Keywords

  • Fundus autofluorescence
  • Microperimetry
  • Natural history
  • Optical coherence tomography
  • Stargardt

ASJC Scopus subject areas

  • Biomedical Engineering
  • Ophthalmology

Cite this

@article{8f00f5ff547443d58ee4e616c144ad26,
title = "A workshop on measuring the progression of atrophy secondary to stargardt disease in the progstar studies: Findings and lessons learned",
abstract = "The Progression of Atrophy Secondary to Stargardt Disease (ProgStar) studies were designed to measure the progression of Stargardt disease through the use of fundus autofluorescence imaging, optical coherence tomography, and microperimetry. The overarching objectives of the studies were to document the natural course of Stargardt disease and identify the most appropriate clinical outcome measures for clinical trials assessing the efficacy and safety of upcoming treatments for Stargardt disease. A workshop organized by the Foundation Fighting Blindness Clinical Research Institute was held on June 11, 2018, in Baltimore, MD, USA. Invited speakers discussed spectral-domain optical coherence tomography, fundus autofluorescence, and microperimetry methods and findings in the ProgStar prospective study. The workshop concluded with a panel discussion of optimal endpoints for measuring treatment efficacy in Stargardt disease. We summarize the workshop presentations in light of the most current literature on Stargardt disease and discuss potential clinical outcome measures and endpoints for future treatment trials.",
keywords = "Fundus autofluorescence, Microperimetry, Natural history, Optical coherence tomography, Stargardt",
author = "{ProgStar Study Group} and Ervin, {Ann Margret} and Strauss, {Rupert W.} and Ahmed, {Mohamed I.} and David Birch and Janet Cheetham and Ferris, {Frederick L.} and Ip, {Michael S.} and Jaffe, {Glenn J.} and Maguire, {Maureen G.} and Sch{\"o}nbach, {Etienne M.} and Sadda, {Srinivas R.} and West, {Sheila K} and Scholl, {Hendrik P.N.}",
year = "2019",
month = "3",
day = "1",
doi = "10.1167/tvst.8.2.16",
language = "English (US)",
volume = "8",
journal = "Translational Vision Science and Technology",
issn = "2164-2591",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "2",

}

TY - JOUR

T1 - A workshop on measuring the progression of atrophy secondary to stargardt disease in the progstar studies

T2 - Findings and lessons learned

AU - ProgStar Study Group

AU - Ervin, Ann Margret

AU - Strauss, Rupert W.

AU - Ahmed, Mohamed I.

AU - Birch, David

AU - Cheetham, Janet

AU - Ferris, Frederick L.

AU - Ip, Michael S.

AU - Jaffe, Glenn J.

AU - Maguire, Maureen G.

AU - Schönbach, Etienne M.

AU - Sadda, Srinivas R.

AU - West, Sheila K

AU - Scholl, Hendrik P.N.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - The Progression of Atrophy Secondary to Stargardt Disease (ProgStar) studies were designed to measure the progression of Stargardt disease through the use of fundus autofluorescence imaging, optical coherence tomography, and microperimetry. The overarching objectives of the studies were to document the natural course of Stargardt disease and identify the most appropriate clinical outcome measures for clinical trials assessing the efficacy and safety of upcoming treatments for Stargardt disease. A workshop organized by the Foundation Fighting Blindness Clinical Research Institute was held on June 11, 2018, in Baltimore, MD, USA. Invited speakers discussed spectral-domain optical coherence tomography, fundus autofluorescence, and microperimetry methods and findings in the ProgStar prospective study. The workshop concluded with a panel discussion of optimal endpoints for measuring treatment efficacy in Stargardt disease. We summarize the workshop presentations in light of the most current literature on Stargardt disease and discuss potential clinical outcome measures and endpoints for future treatment trials.

AB - The Progression of Atrophy Secondary to Stargardt Disease (ProgStar) studies were designed to measure the progression of Stargardt disease through the use of fundus autofluorescence imaging, optical coherence tomography, and microperimetry. The overarching objectives of the studies were to document the natural course of Stargardt disease and identify the most appropriate clinical outcome measures for clinical trials assessing the efficacy and safety of upcoming treatments for Stargardt disease. A workshop organized by the Foundation Fighting Blindness Clinical Research Institute was held on June 11, 2018, in Baltimore, MD, USA. Invited speakers discussed spectral-domain optical coherence tomography, fundus autofluorescence, and microperimetry methods and findings in the ProgStar prospective study. The workshop concluded with a panel discussion of optimal endpoints for measuring treatment efficacy in Stargardt disease. We summarize the workshop presentations in light of the most current literature on Stargardt disease and discuss potential clinical outcome measures and endpoints for future treatment trials.

KW - Fundus autofluorescence

KW - Microperimetry

KW - Natural history

KW - Optical coherence tomography

KW - Stargardt

UR - http://www.scopus.com/inward/record.url?scp=85070319694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070319694&partnerID=8YFLogxK

U2 - 10.1167/tvst.8.2.16

DO - 10.1167/tvst.8.2.16

M3 - Article

C2 - 31019847

AN - SCOPUS:85070319694

VL - 8

JO - Translational Vision Science and Technology

JF - Translational Vision Science and Technology

SN - 2164-2591

IS - 2

M1 - 16

ER -